Ginkgo Bioworks Holdings, Inc. (DNA)

NYSEHealth CareBiotechnologySnapshot 2026-09-04

$6.950.00%

Close 2026-09-04 · 1-day change

QuarterlyIQ Insights · DNA

Financials

Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.

Income Statement

Period

View

Order

Figures in millions of USD, except per-share and ratios.

	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenues
Revenues	132.4	170.2	227.0	251.5	477.7	313.8	76.7
Operating Expenses & Income
R&D Expenses	215.6	243.8	424.1	580.6	1,052.6	1,149.7	159.8
Other Operating Expenses, Total	(5.1)	(4.5)	3.9	9.1	7.6	(1.7)	7.8
Operating Income	(306.1)	(315.3)	(559.8)	(864.4)	(2,209.0)	(1,828.5)	(137.0)
Earnings from Continuing Operations
Interest Expense	—	—	0.1	0.1	0.1	2.4	2.4
Asset Writedown	—	—	4.8	—	—	—	—
EBT, Incl. Unusual Items	—	(313.6)	(547.5)	(892.9)	(2,121.4)	(1,838.1)	(124.8)
Income Tax Expense	(0.6)	(0.8)	(0.5)	(0.1)	(15.0)	(1.5)	1.9
Net Income
Minority Interest	—	—	—	0.0	(1.4)	(6.6)	(0.1)
Net Income	21.6	(312.8)	(547.0)	(0.9)	(2.1)	(1.8)	(126.6)
Per Share
Basic EPS	0.35	(5.64)	(10.54)	(18.37)	(50.15)	(1.35)	(0.10)
Diluted EPS	—	(5.64)	(10.54)	(18.37)	(50.20)	(1.39)	(0.10)
Basic Weighted Avg Shares	62.1	55.5	51.9	48.6	42.0	1,359.8	1,274.8
Diluted Weighted Avg Shares	—	55.5	51.9	48.6	42.0	1,360.4	1,274.8
Supplemental
EBITDA	—	(256.3)	(496.7)	(793.9)	(2,166.4)	(1,799.4)	(123.2)
EBIT	(306.1)	(315.3)	(559.8)	(864.4)	(2,209.0)	(1,828.5)	(137.0)
Effective Tax Rate	—	—	—	0.0%	0.7%	0.1%	-1.5%

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.